$NTRA

Chapman Rowan E sold $643K of NTRA

Chapman Rowan E sold 2,964 shares of Natera, Inc. (NTRA) at $216.78 ($0.64M total) on 2026-06-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Rowan E
Published Jun 18, 2026, 1:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 1:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

This is a disclosed ownership change, but the 10b5-1 pre-arrangement lowers the informational content versus an unplanned sale. Traders may treat it as sentiment/positioning noise rather than a fundamental catalyst.

02

Market read

A director’s 10b5-1 sale is disclosed; potential short-term sentiment impact, but limited expected fundamental effect.

03

What to watch

The article provides only the sale details; it does not indicate whether other insiders bought, whether there were concurrent operational updates, or whether the plan size/frequency signals anything beyond routine selling.

Relevance 4/10Novelty 5/10Timing: Filed 2026-06-17 for a sale executed 2026-06-16

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc., showing a director’s open-market sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera director Chapman Rowan E sold 2,964 shares in an open-market transaction on 2026-06-16 at $216.78/share under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived unless accompanied by other new catalysts.

Evidence & confidence

The filing is a Form 4 insider sale with explicit 10b5-1 pre-arrangement, reducing interpretability as new negative information.

Market effects

Minimal; single-company insider sale does not reset sector expectations.

None indicated.

None indicated.

Counterpoint

10b5-1 sales can be purely liquidity-driven; the market may overreact to the headline without any change in company fundamentals.

Key entities

  • Natera, Inc.

    Issuer of the Form 4 insider transaction; director Chapman Rowan E sold shares under a 10b5-1 plan.

  • Chapman Rowan E

    Director who executed the open-market sale of 2,964 shares on 2026-06-16.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

Jim Cramer Calls Natera (NTRA) “a Promising Story”

Natera (NTRA) reported Q2 revenue of $752.8M, up 37.7% YoY, and raised its 2026 revenue forecast. Jim Cramer called it a promising precision medicine platform but advised waiting for a pullback due to valuation concerns. The company faces competition and regulatory risks, with a net loss of $67M in Q2.

$MRNAHighAI 8/10

Why Moderna's Cancer Vaccine Matters To Investors

Moderna (MRNA) and Merck (MRK) reported successful late-stage trial results for a personalized mRNA cancer vaccine targeting melanoma, reducing recurrence risk by 49%. The treatment relies on technologies from Illumina (ILMN), Danaher (DHR), and others. Moderna's stock surged 176.97% on the news, highlighting the shift toward individualized therapies in oncology.

$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.